Maphoshane Nchabeleng

Dados Biográficos

ID9063133
NOMEMaphoshane Nchabeleng
PRENOMESMaphoshane
SOBRENOMENchabeleng
ASSINATURANCHABELENG M
AFILIAÇÕESSefako Makgatho Health Sciences University
ORCID0000-0003-4385-8915
VERIFICADOSim
TOTAL DE OBRAS2
TOTAL DE CITAÇÕES0
TOTAL COMO AUTOR2
TOTAL COMO EDITOR0
PRIMEIRO ANO DE PUBLICAÇÃO2023
ANO MAIS RECENTE DE PUBLICAÇÃO2024
ÍNDICE H0

  • Safety, effectiveness and immunogenicity of heterologous mRNA-1273 boost after prime with Ad26.COV2.S among healthcare workers in South Africa

    Open AccessNigel Garrett, Tarylee Reddy et al.ARTICLEPLOS Global Public Health2024

    Limited studies have been conducted on the safety and effectiveness of heterologous COVID-19 vaccine boosting in lower income settings, especially those with high-HIV prevalence., The Sisonke Heterologous mRNA-1273 boost after prime with Ad26.COV2.S (SHERPA) trial evaluated a mRNA-1273 boost after Ad26.COV2.S priming in South Africa. SHERPA was a single-arm, open-label, phase 3 study nested in the Sisonke implementation trial of 500000 healthcare…

  • Sexually transmitted infections amongst men who have sex with men (MSM) in South Africa

    Open AccessRujeko Mashingaidze, Zoe Moodie et al.ARTICLEPLOS Global Public Health2023

    There is limited data about bacterial STIs in MSM populations in sub-Saharan Africa. Our retrospective analysis used data from the HVTN 702 HIV vaccine clinical trial (October 2016 to July 2021). We evaluated multiple variables. Polymerase chain reaction testing was conducted on urine and rectal samples to detect Neisseria gonorrhoea (NG) and Chlamydia trachomatis (CT) every 6 months. Syphilis serology was conducted at month 0 and thereafter ever…